Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All substantive claims made are directly supported by the provided FDA label excerpts, including rodent thyroid C-cell tumor findings with unknown human relevance, contraindications for MTC/MEN 2, and patient counseling to report thyroid tumor symptoms.
Category Scores
Accurate Statements
WEGOVY (semaglutide) has a thyroid C-cell tumor risk in rodents, and it is unknown whether it causes thyroid C-cell tumors in humans.
Supported by Sections 5.1 and 13.1 (rodent dose- and duration-dependent thyroid C-cell tumors; human relevance unknown).
WEGOVY is contraindicated in patients with personal or family history of MTC or in patients with MEN 2.
Supported by Section 4 (contraindications) and referenced in Section 5.1.
Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea).
Supported by Section 17 (Risk of Thyroid C-Cell Tumors counseling) and Section 5.1 (symptoms examples).
Unsupported Statements
Contradictions
Important Omissions
The statement does not mention that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection, and that elevated calcitonin may indicate MTC with recommendation for further evaluation.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims provided focus on the core labeled risk (rodent thyroid C-cell tumors with unknown human relevance), the key contraindication (MTC/MEN 2), and symptom counseling; no contradictory or non-labeled safety claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of labeled details regarding calcitonin/ultrasound monitoring uncertainty and evaluation steps for elevated calcitonin.
Suggested Improvement
If expanding the statement, include that routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value and that elevated calcitonin should prompt further evaluation.